Ketoconazole

證據等級: L5

預測適應症: 1 個

Ketoconazole: From Fungal Infections to Acne

One-Sentence Summary

Ketoconazole is an imidazole antifungal originally used to treat fungal skin and systemic infections. The TxGNN model predicts it may also be effective for Acne, with 1 clinical trial and 15 publications currently identified in the evidence pack, though most of this literature is mechanistic or indirect rather than confirmatory.

Quick Overview

Item	Content
Original Indication	Fungal infections (antifungal agent) — no SAHPRA-specific approved indication text on file
Predicted New Indication	Acne
TxGNN Prediction Score	99.80%
Evidence Level	L4
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, ketoconazole is an imidazole antifungal that inhibits fungal cytochrome P450 (lanosterol 14α-demethylase). Separately from its antifungal activity, several of the identified publications describe an off-target effect against Propionibacterium (Cutibacterium) acnes — the bacterium implicated in acne pathogenesis — including direct inhibition of P. acnes lipase and demonstrable in vitro antibacterial activity, which offers a plausible mechanistic bridge to acne.

Ketoconazole’s original use covers fungal and yeast-related dermatological conditions (e.g., dermatophytosis, seborrheic dermatitis, Malassezia-associated disease). Acne and seborrheic dermatitis share overlapping pathophysiology — both involve the sebaceous/follicular unit, sebum metabolism, and local microbial-driven inflammation — which supports biological plausibility for repurposing a topical antifungal already used in adjacent skin conditions.

The strongest mechanistic support comes from two in vitro studies (PMID 28111792, PMID 20045949) showing azole antifungals, including ketoconazole, directly inhibit P. acnes lipase and bacterial growth — the same lipase activity thought to drive comedonal and inflammatory acne lesions. This has now progressed to a randomized, active (not yet completed) trial comparing topical ketoconazole 2% cream against topical adapalene 2% in mild acne (NCT07237763), representing an early translational step from mechanism to clinical testing.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07237763	NA	Active, not recruiting	52	Randomized comparison of topical ketoconazole 2% cream vs. topical adapalene 2% cream in mild comedonal/papulopustular acne; assessing whether ketoconazole is a viable lower-side-effect alternative to retinoids. Estimated completion 2025-12.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28111792	2017	In vitro study	Microbiology and Immunology	Ketoconazole directly inhibits P. acnes lipase activity, the enzyme that metabolizes sebum into pro-inflammatory byproducts; proposed as an alternative to antibiotics amid rising resistance.
20045949	2010	In vitro study	Biological & Pharmaceutical Bulletin	Azole antifungal agents, including ketoconazole, show measurable in vitro activity against P. acnes isolates from acne patients.
8593718	1995	Case series	Clinical and Experimental Dermatology	Pityrosporum folliculitis is frequently misdiagnosed as acne vulgaris; documents diagnostic and therapeutic trial data relevant to differentiating and treating follicular skin disease.
12566804	2003	Review	Dermatology (Basel, Switzerland)	Overview of systemic acne treatment options, noting rising antibiotic resistance and the need for alternative anti-inflammatory/antimicrobial agents.
8255067	1993	Review	The Keio Journal of Medicine	Reviews Pityrosporum ovale’s role across follicular and seborrheic skin diseases, providing background on antifungal relevance to sebaceous-unit conditions.
8629828	1996	Case report	Archives of Dermatology	Describes neonatal Malassezia furfur pustulosis, an acne-mimicking eruption linked to yeast infection, supporting a fungal/microbial contribution to some acneiform presentations.
23600337	2013	Review	FP Essentials	Reviews common infant skin rashes including neonatal acne, noting overlap with microbial follicular conditions.
39622522	2024	Observational study	Southern Medical Journal	Analyzes dermatologic diagnosis and medication dispensing patterns (including antifungals) at a free clinic to optimize formulary stocking.
32872149	2020	Review	Pharmaceuticals (Basel, Switzerland)	Reviews adapalene (the comparator in NCT07237763) as first-line acne therapy, providing context for benchmarking ketoconazole’s potential role.

South Africa Market Information

Ketoconazole currently has no SAHPRA registration on file and is not marketed in South Africa (total registrations: 0). No product-level registration, dosage form, or approved indication data is available for local listing.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for the acne indication currently consists of in vitro/mechanistic studies and a single ongoing (not yet completed) trial — no completed comparative clinical data exists. Critical drug-level safety data (warnings and contraindications) is flagged as a blocking data gap, and the product has no current SAHPRA registration or established South African market presence.

To proceed, the following is needed:

SAHPRA-approved Professional Information (warnings, contraindications) to clear the blocking safety data gap (DG001)
Confirmed mechanism of action data from DrugBank (DG002)
Completed results from NCT07237763 (topical ketoconazole vs. adapalene, estimated completion 2025-12)
A defined regulatory pathway for SAHPRA registration, since the product is not currently marketed in South Africa
Formulation/route data confirming a topical product is available for the acne indication specifically
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.